for more in its first ever GLP1 pill. Guggenheim partner Sheamus Fernandez joins us now. He is the firm's managing director and pharma analyst.Sheamus, great to have you with us. >> Nice to see you. >> Does this change the competitive landscape at all with Eli Liy's or four coming on um and and some other competitors coming, you know, down the pike.>> It's a great question. I mean, I think it doesn't necessarily change the competitive landscape that dramatically. Um but it does give Novo an opportunity to g ...

Core Insights - Novo Nordisk is entering the oral GLP-1 market with its new pill, which may provide an opportunity to gain market share despite not dramatically changing the competitive landscape [2][3] - The success of Novo's pill will depend on its manufacturing capabilities and the ability to meet demand, as the active ingredient requires significantly more quantity compared to injectables [4][5][6] - Consumer preferences will be tested in 2026, determining whether they favor the convenience of a pill over the effectiveness of injectables [7][8][9] Manufacturing and Supply - Novo has begun manufacturing the active ingredient for its pill in North Carolina, but there are concerns about its ability to meet demand due to the complexity of the molecule [4][5] - The pill formulation requires approximately 70 times more of the active ingredient to be effective compared to injectable forms, which poses additional manufacturing challenges [6] Market Dynamics - The introduction of Novo's pill and Eli Lilly's upcoming orforglipron will create a competitive environment where consumer preferences will play a crucial role [3][7] - Eli Lilly has demonstrated effective marketing strategies with its own products, which may influence consumer choices in the market [8][9]

Core Insights - The Chinese biopharmaceutical industry is experiencing significant growth, with 69 innovative drugs approved for market in 2025, surpassing the previous year's total of 48, marking a historical high [1] - China's pharmaceutical industry is now the second largest globally, with approximately 30% of innovative drugs in development worldwide [1] - The industry is entering a new phase of high-quality development, driven by continuous policy support and increased investment from innovative pharmaceutical companies [1] Group 1: Market Trends - The BD (Business Development) boom in 2025 is unprecedented, indicating an increase in the global competitiveness and value of Chinese pharmaceutical assets [3] - China has become the largest source of licensing agreements globally, surpassing the U.S. for the first time, with 90% of the top 20 multinational pharmaceutical companies collaborating with Chinese innovative drug pipelines [3] - The forecast for the next five years suggests a decline in the compound annual growth rate (CAGR) for BD transactions, but it will still maintain double-digit growth [3][4] Group 2: Challenges and Opportunities - Despite the growth, the proportion of first-in-class (FIC) drugs remains low, indicating a need for more original innovations [3] - The majority of BD transactions are still focused on early-stage licensing, with late-stage projects accounting for less than half, leading to potential loss of significant future revenues [3][4] - The Co-Co model, which involves joint development and shared revenue, is emerging but is not expected to become mainstream in the short term due to funding pressures on companies [6][7] Group 3: Investment Landscape - The Hong Kong stock market is currently the leading venue for IPOs of unprofitable biotech companies, with over 60% of shares held by international institutional investors [8][9] - The valuation of biotech companies in Hong Kong is expected to focus on BD capabilities, clinical progress, and global commercialization potential [10][11] - Companies planning to go public in 2026 should emphasize their BD capabilities, clinical advancements, and global market potential to attract investment [11][12] Group 4: Future Directions - The next growth areas for Chinese innovative drugs are expected to include next-generation ADCs, new immuno-oncology drugs, and small nucleic acid drugs, among others [12][13] - Investment trends in the domestic innovative drug sector will increasingly focus on high technical barriers and high commercialization potential, while follow-on innovation projects may face capital withdrawal [13][14]

The S&P 500 (SNPINDEX:^GSPC) rose 0.46% to 6,909.79 near record territory, the Nasdaq Composite (NASDAQINDEX:^IXIC) gained 0.57% to 23,561.84 on tech and healthcare strength, and the Dow Jones Industrial Average (DJINDEX: ^DJI) edged up 0.16% to 48,442.41 in quiet holiday trading. Market movers Obesity-drug leader Novo Nordisk (NYSE:NVO) advanced on FDA approval of its Wegovy pill, lifting healthcare sentiment, while software giant ServiceNow (NYSE:NOW) slid nearly 3% after unveiling a $7.75 billion deal ...

Bristol-Myers Squibb Company (NYSE:BMY) is included among the Best Stocks for a Dividend Achievers List. Bristol-Myers (BMY) Offers Eliquis Free to Medicaid Patients Under New Pricing Pact Several of the largest US and European drugmakers struck agreements with President Donald Trump on December 19 to voluntarily lower the prices of certain medicines. The move comes as the administration pushes to tie US drug prices more closely to lower costs overseas. Bristol-Myers Squibb Company (NYSE:BMY) was part o ...

Hello and welcome to Market Domination. I'm Josh Lipton live from our New York headquarters. It's just an hour to go here until the closing bell and stocks are higher.That's after data showed the US economy expanded at the fastest pace in two years. You've got the Dow up about 75 points. The S&P 500, your broad gauge, that's up about 4/10en of a percent, rising for a fourth straight day there. Your tech heavy NASDAQ, that's up about half a percent.Well, the delayed reading of third quarter economic growth u ...

The U.S. Centers for Medicare and Medicaid Services said on Tuesday it will negotiate drug pricing with manufacturers of GLP-1 medications to expand access to the drugs that help with weight loss. ...

Core Insights - The total addressable market for GLP-1 pills is significant, with over 100 million Americans affected by obesity, indicating a large potential user base for these medications [2][3] - The transition from injectable to oral forms of GLP-1 drugs is expected to increase accessibility and adoption among patients who dislike injections, potentially leading to a higher uptake of these treatments [2][3] Market Dynamics - Novo Nordisk is currently leading the market with its GLP-1 drug, while Eli Lilly is expected to follow closely behind, likely launching its product a few months later [3][4] - The competitive landscape is characterized by a rush to enroll patients before Eli Lilly's product becomes available, as established users may be reluctant to switch medications once they start seeing results [4] Efficacy and Health Impact - Both Novo Nordisk and Eli Lilly's drugs are anticipated to be effective in promoting weight loss and improving related health conditions, with Eli Lilly's product potentially offering slightly better results [5] - A significant increase in the number of users, particularly among those who avoid injections, could lead to improved health outcomes and potentially lower healthcare costs in the long term, despite initial higher expenses associated with these drugs [5][7] Long-term Outlook - The initial phase may see increased healthcare costs due to the high price of these medications, but the long-term health benefits could lead to improved longevity and overall health for the population [6][7] - The focus of these drugs is primarily on health improvement rather than cost reduction, emphasizing the importance of enhancing quality of life and longevity for users [8]

Core Viewpoint - Can-Fite BioPharma Ltd. has announced a 1-for-3,000 reverse split of its ordinary shares, which will take effect on January 2, 2026, with the first trading of the consolidated shares on January 5, 2026 [1][4]. Share Structure Changes - Each outstanding 3,000 pre-split ordinary shares will combine into one new ordinary share automatically, with no action required from shareholders [2]. - The ratio of ordinary shares underlying the Company's American Depositary Shares (ADSs) will change from 1 ADS representing 300 ordinary shares to 1 ADS representing 2 ordinary shares, effective January 5, 2026 [2][3]. - The total number of outstanding ordinary shares will decrease from 42 billion to 14 million as a result of the reverse split [4]. Impact on ADS Holders - For ADS holders, the ratio change equates to a one-for-twenty ADS split, requiring the exchange of every 20 ADSs for one new ADS [3]. - No fractional new ADSs will be issued; instead, fractional entitlements will be aggregated and sold, with net cash proceeds distributed to ADS holders [6]. Ownership and Voting Power - The reverse split and ADS ratio change will not affect shareholders' percentage ownership or voting power, aside from minimal effects from fractional shares [5]. Market Expectations - The ADS price is expected to increase proportionally due to the change in the ADS ratio, although there is no assurance that the price will be equal to or greater than twenty times the pre-split price [7]. Company Overview - Can-Fite BioPharma Ltd. is focused on developing small-molecule drugs for oncological and inflammatory diseases, with its lead drug candidate, Piclidenoson, in Phase III trials for psoriasis [8]. - The company is also advancing Namodenoson, which is in various stages of trials for liver cancer and has received Orphan Drug Designation in the U.S. and Europe [8].

On Dec. 23, 2025, investors weighed a newly approved oral obesity pill’s first-mover edge and its ripple effects across healthcare.NYSE : NVONovo NordiskToday's Change( 7.42 %) $ 3.57Current Price$ 51.67Key Data PointsMarket Cap$162BDay's Range$ 51.05 - $ 53.2052wk Range$ 43.08 - $ 93.80Volume2.1MAvg Vol16MGross Margin81.93 %Dividend Yield3.59 %Novo Nordisk (NVO +7.42%), which develops and markets diabetes and obesity treatments, closed Tuesday’s session at $51.61, up 7.30% after U.S. approval of its once-d ...